New drug PVT201 tested for safety in liver patients
NCT ID NCT06798454
First seen Jan 07, 2026 · Last updated May 15, 2026 · Updated 22 times
Summary
This early-phase study tested a single dose of PVT201 in 24 people to see if it is safe and how the body processes it. Healthy volunteers and patients with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC) took part. The goal was to check for side effects and measure how long the drug stays in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMAX Clinical Research
Adelaide, South Australia, 5000, Australia
Conditions
Explore the condition pages connected to this study.